Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Struggling 2Seventy scraps a key cancer study
2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.
Related Clinical Trials:
Amgen claims success for two immune drugs, but results underwhelm Wall Street
Amgen's Phase 3 results for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis were met with skepticism by analysts, who noted rocatinlimab's underwhelming efficacy and safety concerns, while Uplizna's potential as a second-line treatment was seen as sizable but not a threat to market leaders.
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In ...
Regeneron Pharmaceuticals' P/E, P/B, and P/S ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.
Amgen's Drugs Show Promise in Phase 3 Trials
Amgen's Phase 3 trials for uplizna and rocatinlimab met key endpoints, potentially expanding treatment options and revenue growth. Uplizna targets CD19 to improve myasthenia gravis symptoms, while rocatinlimab shows promise in treating atopic dermatitis. Amgen also won a legal battle against Regeneron, allowing Pavblu's development. Wall Street rates AMGN with a Moderate Buy consensus, projecting 2.54% upside potential.
Regeneron's Eylea biosimilar fight heats up after court ruling
Regeneron shares dropped 5% after a judge denied its request to block Amgen from launching a biosimilar of its drug Eylea, called Pavblu. This ruling contrasts with previous injunctions granted by the same judge against other biosimilars, suggesting Pavblu may not infringe on Regeneron's patent. Regeneron has filed an appeal.
Biotechnology Market Outlook: Growth, Share, Value, Size, and Insights
The biotechnology market, valued at USD 1023.92 Million in 2022, is projected to reach USD 10129.16 Billion by 2030 with a CAGR of 29.00%. Driven by personalized medicine, R&D advancements, and investments, key players like Roche and Thermo Fisher Scientific Inc. are leading innovation. Segmented by technology, application, and end-user, the market spans healthcare, agriculture, and industrial biotechnology, among others.
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Oncolytics Biotech Inc. advances pelareorep therapy, showing significant survival benefits in breast cancer patients. Other biotech companies like Nurix, Incyte, Regeneron, and Foghorn also report promising developments in cancer treatments.
Regeneron Stock Dives As Amgen Tees Up Its Eylea Copycat
A West Virginia judge rejected a preliminary injunction preventing Amgen from launching a biosimilar of Regeneron's eye drug Eylea, causing Regeneron stock to tumble. The FDA approved Amgen's Pavblu, which could launch at risk while the companies are in court. Regeneron plans to appeal, noting the decision only applies to Amgen and the standard dose of Eylea. The court battle could impact Eylea's Medicare negotiations under the Inflation Reduction Act.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
FDA approves Sanofi's Sarclisa for use with Velcade, Bristol Myers' Revlimid, and dexamethasone in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
© Copyright 2025. All Rights Reserved by MedPath